Data / Drug companies / Desloratadine
Desloratadine: 11 companies and 15 products in the FDA NDC directory
Desloratadine is listed in the FDA National Drug Code Directory by 11 companies, with 15 products in commercial distribution. 13 of the products (86.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated; tablet; tablet, orally disintegrating, and the newest product started marketing on August 27, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 11
- Products
- 15
- Generic (ANDA) products
- 13 (86.7%)
- Application numbers
- 7
- Routes
- Oral
- Brand names
- Clarinex
- openFDA record search
- api.fda.gov
Companies that list desloratadine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 3 | tablet, film coated; tablet | Generic drugs (ANDA) | June 12, 2015 |
| Dr. Reddy's Laboratories Limited | 2 | tablet, orally disintegrating | Generic drugs (ANDA) | January 11, 2013 |
| Organon LLC | 2 | tablet, film coated | New drug applications (NDA) | August 23, 2022 |
| Bionpharma Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | November 28, 2023 |
| Bryant Ranch Prepack | 1 | tablet | Generic drugs (ANDA) | June 12, 2015 |
| Bryant Ranch Prepack | 1 | tablet, film coated | Generic drugs (ANDA) | February 25, 2013 |
| Ina Pharmaceutics Inc | 1 | solution | Generic drugs (ANDA) | July 1, 2025 |
| Lupin Pharmaceuticals, Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | February 25, 2013 |
| Morepen Bio Inc | 1 | tablet | Generic drugs (ANDA) | August 27, 2026 |
| Natco Pharma USA LLC | 1 | tablet, film coated | Generic drugs (ANDA) | April 1, 2026 |
| Virtus Pharmaceuticals, LLC | 1 | tablet | Generic drugs (ANDA) | June 12, 2015 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 8 | 53.3% |
| Tablet | 4 | 26.7% |
| Tablet, orally disintegrating | 2 | 13.3% |
| Solution | 1 | 6.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 13 | 86.7% |
| New drug applications (NDA) | 2 | 13.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| Histamine-1 Receptor Antagonist | 15 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.